Cetuximab in non-small cell lung cancer

Foluso O. Ademuyiwa, Nasser Hanna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume8
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Cetuximab
Recurrence
Mutation

Keywords

  • Cetuximab
  • Chemotherapy
  • EGFR antibody
  • Epidermal growth factor receptor inhibitor
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Cetuximab in non-small cell lung cancer. / Ademuyiwa, Foluso O.; Hanna, Nasser.

In: Expert Opinion on Biological Therapy, Vol. 8, No. 1, 01.2008, p. 107-113.

Research output: Contribution to journalArticle

Ademuyiwa, Foluso O. ; Hanna, Nasser. / Cetuximab in non-small cell lung cancer. In: Expert Opinion on Biological Therapy. 2008 ; Vol. 8, No. 1. pp. 107-113.
@article{e223fd11caaf416186bf64a68a57bccb,
title = "Cetuximab in non-small cell lung cancer",
abstract = "Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.",
keywords = "Cetuximab, Chemotherapy, EGFR antibody, Epidermal growth factor receptor inhibitor, Non-small cell lung cancer",
author = "Ademuyiwa, {Foluso O.} and Nasser Hanna",
year = "2008",
month = "1",
doi = "10.1517/14712598.8.1.107",
language = "English",
volume = "8",
pages = "107--113",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Cetuximab in non-small cell lung cancer

AU - Ademuyiwa, Foluso O.

AU - Hanna, Nasser

PY - 2008/1

Y1 - 2008/1

N2 - Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.

AB - Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.

KW - Cetuximab

KW - Chemotherapy

KW - EGFR antibody

KW - Epidermal growth factor receptor inhibitor

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=38949195083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949195083&partnerID=8YFLogxK

U2 - 10.1517/14712598.8.1.107

DO - 10.1517/14712598.8.1.107

M3 - Article

VL - 8

SP - 107

EP - 113

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -